Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats

Neuroscience Letters

Volumn 408, Issue 3, 2006, Pages 189-193

  Wang, Qing ^a,b   Tang, Xian Nan ^b   Wang, Lingzhi ^a   Yenari, Midori A ^b   Ying, Weihai ^b   Goh, Boon Cher ^a   Lee, How Sung ^a   Wilder Smith, Einar P ^a   Wong, Peter T ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

DA; Hydroxymethylglutaryl coenzyme reductase inhibitors; Prefrontal cortex; Rat striatum; Reuptake; Simvastatin

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 33749526659     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.09.009     Document Type: Article

References (37)

1. Abinader E.G. Usefulness of statins in protecting against ventricular arrhythmias. Am. J. Cardiol. 97 (2006) 153-154
2. Adamson P., and Greenwood J. How do statins control neuroinflammation?. Inflamm. Res. 52 (2003) 399-403
3. Baptista T., Lacruz A., Paez X., Hernandez L., and Beaulieu S. The antipsy chotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?. Eur. J. Pharmacol. 447 (2002) 91-98
4. Carlsson A., and Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J. Neurol. Trans. 38 (1976) 271-276
5. Dazzi L., Motzo C., Imperato A., Serra M., Gessa G.L., and Biggio G. Modulation of basal and stress-induced release of acetylcholine and dopamine in rat brain by abecarnil and imidazenil, two anxioselective gamma-aminobutyric acidA receptor modulators. J. Pharmacol. Exp. Ther. 273 (1995) 241-247
6. Dazzi L., Seu E., Cherchi G., and Biggio G. Inhibition of stress-induced dopamine output in the rat prefrontal cortex by chronic treatment with olanzapine. Biol. Psychiatry 55 (2004) 477-483
7. Gonon F. Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. J. Neurosci. 17 (1997) 5972-5978
8. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
9. Hornykiewicz O., Kish S.J., Becker L.E., Farley I., and Shannak K. Brain neurotransmitters in dystonia musculorum deformans. N. Engl. J. Med. 315 (1986) 347-353
10. Howard-Jones N. A CIOMS ethical code for animal experimentation. WHO Chronic 39 (1985) 1-56
11. Hutson P.H., and Barton C.L. L-701,324, a glycine/NMDA receptor antagonist, blocks the increase of cortical dopamine metabolism by stress and DMCM. Eur. J. Pharmacol. 326 (1997) 127-132
12. Javoy-Agid F., Ploska A., and Agid Y. Microtopography of tyrosine hydroxylase, glutamic acid decarboxylase, and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and Parkinsonian brains. J. Neurochem. 37 (1981) 1218-1227
13. Jones P. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 81 (1998) 582-587 (Erratum in: Am. J. Cardiol. 82 (1) 128)
14. Kawashima S., Yamashita T., Miwa Y., Ozaki M., Namiki M., Hirase T., Inoue N., Hirata K., and Yokoyama M. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 34 (2003) 157-163
15. Kish S.J., Shannak K., Rajput A., Deck J.H.N., and Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58 (1992) 642-648
16. Konstandi M., Johnson E., Lang M.A., Malamas M., and Marselos M. Noradrenaline, dopamine, serotonin: different effects of psychological stress on brain biogenic amines in mice and rats. Pharmacol. Res. 41 (2000) 341-346
17. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 (2003) 1423-1429
18. Lea A.P. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 53 (1997) 828-847
19. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275 (2000) 38581-38588
20. Lu D., Goussev A., Chen J., Pannu P., Li Y., Mahmood A., and Chopp M. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J. Neurotrauma 21 (2004) 21-32
21. Max J.E., Fox P.T., Lancaster J.L., Kochunov P., Mathews K., Manes F.F., Robertson B.A., Arndt S., Robin D.A., and Lansing A.E. Putamen lesions and the development of attention-deficit/hyperactivity symptomatology. J. Am. Acad. Child Adolesc. Psychiatry 41 (2002) 563-571
22. Mckenney J.M. Potential nontraditional applications of statins. Ann. Pharmacother. 37 (2003) 1063-1071
23. 2 receptors. J. Neurosci. Res. 55 (1999) 600-607
24. Orr C.F., Rowe D.B., Mizuno Y., Mori H., and Halliday G.M. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128 Part 11 (2005) 2665-2674
25. Roglans N., Verd J.C., Peris C., Alegret M., Vazquez M., Adzet T., Diaz C., Hernandez G., Laguna J.C., and Sanchez R.M. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 37 (2002) 445-454
26. Rosetti Z.L., Pani L., Portas C., and Gessa G. Brain dialysis provides evidence for D2-dopamine receptors modulating noradrena-line release in the rat frontal cortex. Eur. J. Pharmacol. 163 (1989) 393-395
27. Schoonjans K., Peinado-Onsurbe J., Fruchart J.C., Tailleux A., Fievet C., and Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 452 (1999) 160-164
28. Steffens M., and Feuerstein T.J. Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex-involvement of Na (+)/K(+)-ATPase. Neurochem. Int. 44 (2004) 529-538
29. Stein E.A. Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 81 (1998) 66B-69B
30. Suzuki T., Ishigooka J., Watanabe S., and Miyaoka H. Enhancement of delayed release of dopamine in the amygdala induced by conditioned fear stress in methamphetamine-sensitized rats. Eur. J. Pharmacol. 435 (2002) 59-65
31. Terblanche M., Almog Y., Rosenson R.S., Smith T.S., and Hackam D.G. Statins: panacea for sepsis?. Lancet Infect. Dis. 6 (2006) 242-248
32. Ton T.G., Heckbert S.R., Lipton A.M., Longstreth Jr. W.T., Rossing M.A., Kukull W.A., Franklin G.M., Swanson P.D., Smith-Weller T., and Checkoway H. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov. Disord. (2006) (Epub ahead of print)
33. Vega G.L., Weiner M.F., Lipton A.M., Von Bergmann K., Lutjohann D., Moore C., and Svetlik D. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 60 (2003) 510-515
34. 2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br. J. Pharmacol. 144 (2005) 933-939
35. Wang Q., Wang P.H., McLachlan C., and Wong P.T. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 1045 (2005) 229-233
36. Westerink B.H., de Boer P., de Vries J.B., Kruse C.G., and Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur. J. Pharmacol. 361 (1998) 27-33
37. Zhang Y., Wang W., and Zhang J. Effects of novel anxiolytic 4-butyl-alpha-agarofuran on levels of monoamine neurotransmitters in rats. Eur. J. Pharmacol. 504 (2004) 39-44